What We're Reading: Page 164
Industry reads hand-picked by our editors
Jul 29, 2021
-
Endpoints News
In CureVac's failure, a possible verdict on the past (and future) of mRNA vaccines
-
Nature
How the coronavirus infects cells — and why Delta is so dangerous
-
MedCity News
AI-driven Deep Genomics gets $180M to turn biology into informational medicines
-
Fierce Biotech
GSK culls phase 2 RSV vaccine in kids, as feladilimab flops again in lung cancer
Jul 28, 2021
Jul 27, 2021
-
The New York Times
At the F.D.A.’s urging, Pfizer-BioNTech and Moderna are expanding their studies of children 5 to 11.
-
The Washington Post
‘A tipping point’: Government officials, health groups move to require coronavirus vaccines for workers
-
Fierce Biotech
Artios raises $153M to fund DNA damage repair clinical trials
Jul 26, 2021
-
Chemical & Engineering News
Francis Collins on the urgent need for COVID-19 antivirals
-
The Guardian
‘A cartel shouldn’t get away with this.’ Anger at opioid settlements that exclude admission of wrongdoing
-
The Wall Street Journal
The Delta Variant and Covid-19 Vaccines: What to Know
-
BioCentury
Borio adds public health, biodefense chops to Arch
Jul 23, 2021
-
The New York Times
A.I. Predicts the Shapes of Molecules to Come
-
The Wall Street Journal
U.S. Vaccine Panel Signals Preliminary Support for Covid-19 Booster Shots
-
FierceBiotech
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
-
The Boston Globe
Another white male CEO at MassBio? The group has some explaining to do
Jul 22, 2021
-
Evaluate Vantage
The Delta for Covid-19 vaccine efficacy
-
The New York Times
Ken Frazier, the former Merck chief, is heading to venture capital
-
Reuters
Roche in talks with FDA on Alzheimer's candidate, says CEO
Previous
